Black Diamond Therapeutics Inc (BDTX) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Black Diamond Therapeutics Inc stock (BDTX) is currently trading at $2.14. Black Diamond Therapeutics Inc PE ratio is 5.70. Black Diamond Therapeutics Inc PS ratio (Price-to-Sales) is 1.72. Analyst consensus price target for BDTX is $9.71. WallStSmart rates BDTX as Hold.
- BDTX PE ratio analysis and historical PE chart
- BDTX PS ratio (Price-to-Sales) history and trend
- BDTX intrinsic value — DCF, Graham Number, EPV models
- BDTX stock price prediction 2025 2026 2027 2028 2029 2030
- BDTX fair value vs current price
- BDTX insider transactions and insider buying
- Is BDTX undervalued or overvalued?
- Black Diamond Therapeutics Inc financial analysis — revenue, earnings, cash flow
- BDTX Piotroski F-Score and Altman Z-Score
- BDTX analyst price target and Smart Rating
Black Diamond Therapeutics Inc
📊 No data available
Try selecting a different time range
BDTX Intrinsic Value Analysis for Value Investors
Benjamin Graham Formula · Black Diamond Therapeutics Inc (BDTX)
BDTX is trading near its Graham intrinsic value of $2.52, suggesting the stock is reasonably priced at current levels.
Based on Benjamin Graham Formula. Growth rate capped at 25%. For informational purposes only. Not financial advice.
Smart Analysis
Black Diamond Therapeutics Inc (BDTX) · 7 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in return on equity, operating margin, price/sales. Concerns around market cap. Fundamentals are solid but monitor weak areas for improvement.
Black Diamond Therapeutics Inc (BDTX) Key Strengths (6)
Trading below book value, meaning the market prices it less than net assets
Keeps $32 of every $100 in revenue as net profit
77.45% of shares held by major funds and institutions
Every $100 of equity generates $23 in profit
Strong operational efficiency: $28 kept per $100 revenue
Paying $1.72 for every $1 of annual revenue
Supporting Valuation Data
Black Diamond Therapeutics Inc (BDTX) Areas to Watch (1)
Micro-cap company with very limited liquidity and high volatility
Black Diamond Therapeutics Inc (BDTX) Detailed Analysis Report
Overall Assessment
This company scores 59/100 in our Smart Analysis, earning a C grade. Out of 7 metrics analyzed, 6 register as strengths (avg 9.2/10) while 1 fall into concern territory (avg 3.0/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Price/Book, Profit Margin, Institutional Own.. Valuation metrics including Price/Sales (1.72), Price/Book (0.95) suggest the stock is attractively priced. Profitability is solid with Return on Equity at 22.90%, Operating Margin at 28.40%, Profit Margin at 32.00%.
The Bear Case
The primary concerns are Market Cap.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Market Cap improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at 22.90% currently healthy but needing to be sustained. Third, top-line growth trajectory.
Risk Considerations
Based on the metric profile, this is a moderate-to-high risk investment. The weight of evidence leans positive, with more strengths than concerns. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Mixed fundamentals with both positives (Price/Book, Profit Margin) and negatives (Market Cap). A cautious approach is warranted. Monitor for improvement in weak areas before increasing conviction.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
BDTX Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
BDTX's Price-to-Sales ratio of 1.72x sits near its historical average of 1.84x (0th percentile), suggesting the market is pricing in steady-state growth. The current valuation is 16% below its historical high of 2.04x set in Feb 2026, and 0% above its historical low of 1.72x in Mar 2026. Over the past 12 months, the PS ratio has compressed from ~2.0x as trailing revenue scaled faster than the stock price.
WallStSmart Analysis Synopsis
Data-driven financial summary for Black Diamond Therapeutics Inc (BDTX) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Black Diamond Therapeutics Inc operates as a stable business with moderate growth and solid fundamentals. Profit margins are strong at 32.0%, reflecting pricing power and operational efficiency.
Key Findings
ROE of 22.9% means the company generates strong returns on shareholder equity. Above 20% is considered top-tier.
Profit margin of 32.0% and operating margin of 28.4% demonstrate strong pricing power and operational efficiency.
Free cash flow is -7M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Volatility is elevated with a beta of 3.43, so expect amplified moves relative to the broader market.
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Black Diamond Therapeutics Inc.
Bottom Line
Black Diamond Therapeutics Inc offers stability with moderate growth and solid fundamentals. The valuation may present an opportunity for patient investors, though limited growth means returns will likely come from dividends and modest capital appreciation rather than explosive gains.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Black Diamond Therapeutics Inc(BDTX)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Black Diamond Therapeutics, Inc., a biotechnology company, discovers and develops small molecule tumor agnostic therapies. The company is headquartered in Cambridge, Massachusetts.